Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 26;56(5):2000075.
doi: 10.1183/13993003.00075-2020. Print 2020 Nov.

The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops

Affiliations
Review

The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops

Ashley R Rackow et al. Eur Respir J. .

Abstract

Pulmonary fibrosis is a devastating, progressive disease and carries a prognosis worse than most cancers. Despite ongoing research, the mechanisms that underlie disease pathogenesis remain only partially understood. However, the self-perpetuating nature of pulmonary fibrosis has led several researchers to propose the existence of pathological signalling loops. According to this hypothesis, the normal wound-healing process becomes corrupted and results in the progressive accumulation of scar tissue in the lung. In addition, several negative regulators of pulmonary fibrosis are downregulated and, therefore, are no longer capable of inhibiting these feed-forward loops. The combination of pathological signalling loops and loss of a checks and balances system ultimately culminates in a process of unregulated scar formation. This review details specific signalling pathways demonstrated to play a role in the pathogenesis of pulmonary fibrosis. The evidence of detrimental signalling loops is elucidated with regard to epithelial cell injury, cellular senescence and the activation of developmental and ageing pathways. We demonstrate where these loops intersect each other, as well as common mediators that may drive these responses and how the loss of pro-resolving mediators may contribute to the propagation of disease. By focusing on the overlapping signalling mediators among the many pro-fibrotic pathways, it is our hope that the pulmonary fibrosis community will be better equipped to design future trials that incorporate the redundant nature of these pathways as we move towards finding a cure for this unrelenting disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.R. Rackow has nothing to disclose. Conflict of interest: D.J. Nagel reports grants from National Heart, Lung, and Blood Institution (NIH T32 training grant), during the conduct of the study. Conflict of interest: C. McCarthy has nothing to disclose. Conflict of interest: J. Judge has nothing to disclose. Conflict of interest: S. Lacy is employed by the US Army; the views expressed herein are those of the author and do not reflect the official policy or position of the Department of the Army, Department of Defense or the US Government. Conflict of interest: M.A.T. Freeberg has nothing to disclose. Conflict of interest: T.H. Thatcher reports grants from NIH, during the conduct of the study. Conflict of interest: R.M. Kottmann reports grants from NIH, during the conduct of the study; and has a patent for LDH inhibitors as treatment for fibrosis and fibrotic-related disorders issued. Conflict of interest: P.J. Sime reports grants from NIH, during the conduct of the study; grants from NIH, grants and personal fees for consultancy from UCB, personal fees for consultancy from Boehringer Ingelheim, personal fees from GSK, personal fees for data monitoring committee work from Intermune/Roche, personal fees for advisory board work from Prometic and Galecto, and funds for research from Guy Solimano and Greg Chandler Fund, outside the submitted work; and has a patent for methods of diagnosing and treating fibrosis issued, a patent for LDH inhibitors as treatment for fibrosis and fibrotic-related disorders issued, and a patent for method and apparatus to diagnose metastatic and progressive potential of cancer, fibrosis and other diseases pending.

Figures

FIGURE 1
FIGURE 1
Overview of the interaction among various feed-forward loops involved in pulmonary fibrosis whereby all pathways to the development of the disease.
FIGURE 2
FIGURE 2
Recurrent epithelial injury leads to chronic activation of transforming growth factor-β1 (TGF-β1) and Wingless/Integrase-1 (Wnt) signalling cascades. The activation of TGF-β1 can suppress negative regulators of the Wnt pathway and ultimately activate Wnt signalling. Activation of Wnt signalling also propagates TGF-β1 signalling. This, coupled with chronic epithelial damage, further drives this cycle to result in pathological, unresolving wound healing. DKK1: Dickkopf-1
FIGURE 3
FIGURE 3
Signalling cartoon of the interaction among transforming growth factor-β1 (TGF-β1), epithelial–mesenchymal transition (EMT), epithelial injury, oxidative stress, telomere attrition and senescence. Red boxes depict pro-fibrotic pathways and green boxes indicate anti-fibrotic ones. TGFBR2: transforming growth factor-β receptor-2; PTEN: phosphatase and tensin homolog; JAK: Janus-activated kinase; p38 MAPK: p38 mitogen-activated kinase; PI3K: phosphatidylinositol-3 kinase; AMPK: 5′-AMP activated kinase; mTOR: mammalian target of rapamycin; AP-1: activator protein-1; SIRT: sirtuin protein family; VEGF: vascular endothelial growth factor; SASP: senescence-associated secretory phenotype.

References

    1. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2017; 5: 33–41. - PubMed
    1. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med 2016; 113: 74–79. - PubMed
    1. Judge JL, Nagel DJ, Owens KM, et al. Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol. PLoS One 2018; 13: e0197936. - PMC - PubMed
    1. Liu F, Lagares D, Choi KM, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol 2015; 308: L344–L357. - PMC - PubMed
    1. Nguyen XX, Muhammad L, Nietert PJ, et al. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators. Front Endocrinol (Lausanne) 2018; 9: 601. - PMC - PubMed

Publication types